Description Results NMA

all causes death 0.98 [0.89; 1.07]

amputation 0.89 [0.60; 1.32]

CVdeath 1.00 [0.89; 1.13]

fatal and non fatal stroke 1.03 [0.88; 1.20]

fatal and non fatal MI 1.02 [0.88; 1.19]

Hospitalization for heart failure 0.90 [0.77; 1.05]

CV events 1.02 [0.94; 1.11]

Microvascular event 0.97 [0.90; 1.05]

insulin glargine (with a target fasting blood glucose level of ¡Ü95 mg per deciliter (n=6264)

vs.

standard care (n=6273)

Sample size: 6264/6273

Primary endpoint:

FU duration: 6.2 years

HF hospitalization 0.74 [0.66; 0.83]

hospitalization for Cv reason 0.85 [0.78; 0.92]

CV deaths, hospitalization for HF, MI 0.82 [0.75; 0.90]

cardiovascular deaths or heart-failure hospitalisations 0.82 [0.75; 0.90]

Death from heart failure 0.74 [0.58; 0.94]

All cause death 0.90 [0.80; 1.02]

cardiovascular death 0.92 [0.82; 1.04]

ivabradine (n=3241)

vs.

placebo (n=3264)

double-blind

Parallel groups

Sample size: 3241/3264

Primary endpoint: cardiovascular death or hospitalization for heart failure

FU duration: 23 months